Us Patent & Tradement Office, U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMS control number

ostitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

	Complete if Known
Application Number	10/813,209
Filing Date	March 29, 2004
First Named Inventor	Hofmann, Gunter
Art Unit	3763
Examiner Name	Koharski, Christopher

(Use as many sheets as necessary)

Sheet 1 of 2 Attorney Docket No: GTI-1360-CT

US PATENT DOCUMENTS					
Examiner initial *	Cite No	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Filing Date If Appropriate
/CK/	1	2,754,818	07 Jul 1956	Scherer	
	2	3,805,783	23 Apr 1974	Ismash	
	3	4,342,310	03 Aug 1982	Lindmayer et al	
	4	4,447,223	08 May 1984	Kaye et al	<u> </u>
	5	4,752,285	21 Jun 1988	Petelenz et al	
	6	5,013,293	07 May 1991	Sibalis	
	7	5,019,034	28 May 1991	Weaver et al	
	8	5,273,525	28 Dec 1993	Hofmann	
	9	5,389,069	14 Feb 1995	Weaver	
	10	5,468,223	21 Nov 1995	Mir	
	11	5,505,697	09 Apr 1996	McKinnon et al	
	12	5,506,125	09 Apr 1996	McCabe et al	
	13	5,547,467	20 Aug 1996	Pliquett et al	
	14	5,551,953	03 Sep 1998	Lattin et al	
	15	5,589,466	31 Dec 1996	Feigner et al	
	16	5,599,302	04 Feb 1997	Lilley et al	
	17	5,667,491	16 Sep 1997	Pliquett et al	
	18	5,702,359	30 Dec 1997	Hofmann et al	
	19	5,857,492	12 Jan 1999	Haak et al	
	20	5,993,434	30 Nov 1999	Dev et al	
	21	6,035,234	07 Mar 2000	Riddle et al	
	22	6,086,572	11 Jul 2000	Johnson et al	
	23	6,148,232	14 Nov 2000	Avrahami ·	
	24	6,192,270	20 Feb 2001	Hofmann	
	25	6,328,728	11 Dec 2001	Holladay et al	
-+	26	6,520,950	18 Feb 2003	Hofmann et al	
/CK/	27	2002/0102729	01 Aug 2002	MacLaughlin et al	

	-		FOREIGN F	PATENT DOCUMENTS	
Examiner Initials*	Cite	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of cited Document	, T ²

.,,,,,,	OTHE	R DOCUMENTS NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T'
/CK/	28	BOQUET et al. "Binding of triton X-100 to diphtheria toxin, crossreacting material 45, and their fragments," Proc. Natl. Acad. Sci. USA 73(12):4449-4453 (1976)	
	29	CECH, "Ribozymes and their medical implications," J. Amer. Med. Assn. 260:3030-3034 (1988)	
	30	DINH et al, "Upper and Lower Limits of Human Skin Electrical Resistance in lontophoresis," AIChe J. 39:2011-2018 (1993)	
/CK/	31	DONNELLY et al., "DNA vaccines," Annu. Rev. Immunol. 15:617-648 (1997)	

EXAMINER

/Christopher Koharski/

DATE CONSIDERED

01/18/2008

PTO/SB/08a(04-07)
Approved for use through 7/3/2006, OMB 0551-0031
US Petent & Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paparwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

e for form 1449A/PTO

Complete If Known
10/813,209
March 29, 2004
Hofmann, Gunter
3763
Koharski, Christopher

(Use as many sheets as necessary)

Attorney Docket No: GTI-1360-CT Sheet of

/CK/	32	HASELOFF et al, "Simple RNA enzymes with new and highly specific endoribonuclease activities," Nature 334:585-591 (1988)	
	33	HELENE, "The anti-gene strategy: control of gene expression by triplex-forming-oligonucleotides," Anticancer Drug Design 6(6):569-584 (1991)	
	34	KRIEG et al., "Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs, " Proc. Natl. Acad. Sci. USA 95:12631-12636 (1998)	
	35	McCULLOCH, "The contribution of blast cell properties to outcome variation in acute myeloblastic leukemia," Blood 59:801-608 (1982)	
	36	MAHER III, "Oligonucleotide-Directed DNA Triple-Helix Formation: An Approach to Artificial Repressors?," Anti. Res and Dev. 1:277-281 (1991)	
	37	MARCUS-SEKURA, "Techniques for Using Antisense Oligodeoxyribonucleotides to Study Gene Expression," Anal. Bio, 172:289-295 (1988)	
	38	RICHMOND et al., "Studies of the neutralizing activity and avidity of anti-human immunodeficiency virus type 1 Env antibody elicited by DNA priming and protein boosting," <i>J. Virol.</i> 72:9092-9100 (1998)	
	39	ROBINSON et al., "Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations," Nat. Med. 5:526-534 (1999)	
	40	TANG et al., "Genetic immunization is a simple method for eliciting an immune response," Nature 356:152-154 (1992)	
	41	'THORPE et al., "An immunotoxin composed of monoclonal anti-Thy 1.1 antibody and a ribosome-inactivating protein from Saponaria officinalis: potent antitumor effects in vitro and in vivo," <i>J. National Cancer Institute</i> 75:151-159 (1985)	
	42	ULMER et al., "Heterologous protection against influenza by injection of DNA encoding a viral protein," Science 259:1745-1749 (1993)	
	43	WEERATNA et al., *Reduction of antigen expression from DNA vaccines by coadministered oligodeoxynucleotides,* Antisense Nucleic Acid Drug Dev. 8(4):351-356 (1998)	
	44	WEINTRAUB, "Antisense RNA and DNA," Scientific American 262:40-46 (1990)	
/CK/	45	YEUNG et al., "Purification of three isolectins from root tubers of trishozanthes kirilowii (Tianhuafen)," Intl. J. of Peptide Protein Res. 27:325-333 (1985)	

EXAMINER

/Christopher Koharski/

DATE CONSIDERED

01/18/2008